Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company specializing in oral drug delivery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually.
Dr. Mahesh V. Patel, President and CEO of Lipocine, will present at the conference and meet with investors. The presentation will be available from 7:00 a.m. EDT on Monday, September 9, 2024. Interested parties can access the webcast through the provided link. Investors wishing to arrange one-on-one meetings with Lipocine representatives should contact their H.C. Wainwright representative.
Lipocine Inc. (NASDAQ: LPCN), un'azienda biofarmaceutica specializzata nella somministrazione orale di farmaci, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento, previsto dal 9 all'11 settembre 2024, si svolgerà sia in presenza che virtualmente.
Il Dr. Mahesh V. Patel, Presidente e CEO di Lipocine, presenterà durante la conferenza e incontrerà gli investitori. La presentazione sarà disponibile a partire dalle 7:00 a.m. EDT di lunedì 9 settembre 2024. Le parti interessate possono accedere al webcast tramite il link fornito. Gli investitori che desiderano organizzare incontri one-to-one con i rappresentanti di Lipocine dovrebbero contattare il loro rappresentante H.C. Wainwright.
Lipocine Inc. (NASDAQ: LPCN), una compañía biofarmacéutica especializada en la administración oral de medicamentos, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento, programado del 9 al 11 de septiembre de 2024, se llevará a cabo tanto de manera presencial como virtual.
El Dr. Mahesh V. Patel, Presidente y CEO de Lipocine, presentará en la conferencia y se reunirá con inversores. La presentación estará disponible a partir de las 7:00 a.m. EDT del lunes 9 de septiembre de 2024. Las partes interesadas pueden acceder al webcast a través del enlace proporcionado. Los inversores que deseen organizar reuniones uno a uno con los representantes de Lipocine deben contactar a su representante de H.C. Wainwright.
Lipocine Inc. (NASDAQ: LPCN), 경구 약물 전달을 전문으로 하는 생명공학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 대면과 온라인으로 진행됩니다.
Lipocine의 회장 겸 CEO인 Dr. Mahesh V. Patel은 컨퍼런스에서 발표하고 투자자들과 만날 예정입니다. 발표는 2024년 9월 9일 월요일 오전 7:00 EDT부터 이용 가능합니다. 관심 있는 분들은 제공된 링크를 통해 웹캐스트에 접속할 수 있습니다. Lipocine의 대표들과 일대일 회의를 주선하고자 하는 투자자는 H.C. Wainwright 대표에게 연락해야 합니다.
Lipocine Inc. (NASDAQ: LPCN), une société biopharmaceutique spécialisée dans l'administration orale de médicaments, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement, prévu du 9 au 11 septembre 2024, se tiendra à la fois en personne et virtuellement.
Le Dr Mahesh V. Patel, Président et CEO de Lipocine, fera une présentation à la conférence et rencontrera des investisseurs. La présentation sera disponible à partir de 7h00 EDT le lundi 9 septembre 2024. Les parties intéressées peuvent accéder à la diffusion en direct via le lien fourni. Les investisseurs souhaitant organiser des réunions individuelles avec des représentants de Lipocine doivent contacter leur représentant H.C. Wainwright.
Lipocine Inc. (NASDAQ: LPCN), ein biopharmazeutisches Unternehmen, das sich auf die orale Arzneimittelverabreichung spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz H.C. Wainwright angekündigt. Die Veranstaltung, die vom 9. bis 11. September 2024 stattfinden wird, findet sowohl persönlich als auch virtuell statt.
Dr. Mahesh V. Patel, Präsident und CEO von Lipocine, wird auf der Konferenz präsentieren und sich mit Investoren treffen. Die Präsentation wird ab 7:00 Uhr EDT am Montag, den 9. September 2024 verfügbar sein. Interessierte Parteien können über den bereitgestellten Link auf das Webcast zugreifen. Investoren, die Einzelgespräche mit Vertretern von Lipocine arrangieren möchten, sollten ihren Vertreter von H.C. Wainwright kontaktieren.
- None.
- None.
Presentation Details
Time: Available from 7:00 a.m. EDT onwards
Date: Monday, September 9, 2024
Webcast Link: https://journey.ct.events/view/50f7964c-3a38-4f56-9dfa-454d6c66e39f
Investors can register for the conference here. Those interested in arranging a 1x1 meeting with Lipocine should contact their H.C. Wainwright representative.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in chronic weight management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for chronic weight management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-hc-wainwright-26th-annual-global-investment-conference-302230689.html
SOURCE Lipocine Inc.
FAQ
When is Lipocine (LPCN) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing Lipocine (LPCN) at the H.C. Wainwright conference?
How can investors access Lipocine's (LPCN) presentation at the H.C. Wainwright conference?
What is the date range for the H.C. Wainwright 26th Annual Global Investment Conference featuring Lipocine (LPCN)?
How can investors arrange a one-on-one meeting with Lipocine (LPCN) at the H.C. Wainwright conference?
